Hypercalcaemia in an immunocompromised patient: consider Pneumocystis jirovecii pneumonia

Karen Bromley, Jessica Phillips and Ashley Irish
Med J Aust 2022; 217 (10): . || doi: 10.5694/mja2.51761
Published online: 21 November 2022

A 71‐year‐old man with a history of 6 weeks of generalised decline presented for outpatient clinic assessment. Initial symptoms included fatigue, weakness, and anorexia causing 6 kg weight loss. His medical history was significant for a live‐related renal transplant 20 years earlier for membranous glomerulonephritis, insulin‐dependent type 2 diabetes mellitus, a right native nephrectomy 12‐months prior for clear cell renal cell carcinoma (Grade 3, pT1a), and multiple basal and squamous cell carcinomas of the skin. Maintenance immunosuppression was with mycophenolate mofetil 1 g twice a day and cyclosporine 50 mg twice a day without prednisolone. He had received one infusion of rituximab 800 mg 4 months earlier for biopsy‐proven recurrent membranous glomerulonephritis. Further history and examination did not reveal any localising symptoms or signs.

  • Fiona Stanley Hospital, Perth, WA

Competing interests:

No relevant disclosures.

  • 1. Permpalung N, Kittipibul V, Mekraksakit P, et al. A comprehensive evaluation of risk factors for Pneumocystis jirovecii pneumonia in adult solid organ transplant recipients: a systematic review and meta‐analysis. Transplantation 2021; 105: 2291‐2306.
  • 2. Kamanski H, Belliere J, Burguet L, et al. Identification of predictive markers and outcomes of late‐onset Pneumocystis jirovecii pneumonia in kidney transplant recipients. Clin Infect Dis 2020; 73: 1456‐1463.
  • 3. Park JW, Curtis JR, Jun KI et al. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest 2022; 161: 1201‐1210.
  • 4. Hamroun A, Lenain R, Nguyen LB et al. Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients. Nature 2019; 9: 12508.
  • 5. Tebben PJ, Ravinder JS, Kumar R. Vitamin D‐mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev 2016; 37; 521‐547.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.